Balance Sheet
Accounts PayablesAccumulated DepreciationAccumulated ExpensesAssetsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueLiabilities and Shareholders EquityLong-Term InvestmentsNon-Current AssetsNon-Current Deffered RevenueOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Property, Plant & Equipment (Net)ReceivablesReceivables - NetReceivables - OtherRetained EarningsShareholder's EquityShares OutstandingTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Stoke Therapeutics (STOK) Cash & Equivalents (2021 - 2025)

Stoke Therapeutics has reported Cash & Equivalents over the past 5 years, most recently at $84.2 million for Q4 2025.

  • For Q4 2025, Cash & Equivalents fell 34.19% year-over-year to $84.2 million; the TTM value through Dec 2025 reached $84.2 million, down 34.19%, while the annual FY2025 figure was $84.2 million, 34.19% down from the prior year.
  • Cash & Equivalents for Q4 2025 was $84.2 million at Stoke Therapeutics, up from $83.4 million in the prior quarter.
  • Over five years, Cash & Equivalents peaked at $274.8 million in Q1 2025 and troughed at $67.8 million in Q2 2022.
  • A 5-year average of $146.0 million and a median of $144.9 million in 2021 define the central range for Cash & Equivalents.
  • Biggest five-year swings in Cash & Equivalents: skyrocketed 183.47% in 2023 and later crashed 47.55% in 2025.
  • Year by year, Cash & Equivalents stood at $144.9 million in 2021, then decreased by 21.63% to $113.6 million in 2022, then surged by 68.59% to $191.4 million in 2023, then crashed by 33.15% to $128.0 million in 2024, then tumbled by 34.19% to $84.2 million in 2025.
  • Business Quant data shows Cash & Equivalents for STOK at $84.2 million in Q4 2025, $83.4 million in Q3 2025, and $101.5 million in Q2 2025.